The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Fundraising

7 Apr 2008 15:46

Amphion Innovations PLC07 April 2008 Amphion Innovations plc Fundraising and Directors Dealings London and New York, 7 April 2008 - Amphion Innovations plc (LSE: AMP)("Amphion" or the "Company"), the developer of medical and technologybusinesses, today announces that it has raised £250,000 (before expenses) by theissue of 1,136,364 new ordinary shares of 1p each in the capital of the Company(the "New Ordinary Shares") to an institutional investor by way of subscriptionat an issue price of 22 pence per New Ordinary Share to enable the Company toinvest in current and new Partner Companies and to provide working capital forthe Company. The New Ordinary Shares will represent approximately 0.87 per centof the existing Amphion share capital. Application will be made to the London Stock Exchange for the New OrdinaryShares to be admitted to trading on AIM. The New Ordinary Shares will, whenissued, rank equally in all respects with the existing Ordinary Shares,including the right to receive any dividend or other distribution declared, madeor paid following Admission. It is expected that Admission will become effectiveand that dealings in the New Ordinary Shares will commence 11 April 2008. Amphion also announces today that New Ordinary Shares have been issued to Boardmembers Richard Mansell-Jones and R. James Macaleer who, in lieu of theirdirectors' fee for the period 1 January to 31 March 2008, received their fullremuneration in the form of Ordinary Shares priced at 22p being the closingmid-market price on 1 April 2008. Richard Mansell-Jones, Chairman of Amphion, received 40,227 Ordinary Shares,bringing his total holdings of the Company to 2,602,792 representing 2 per centof the Company's issued Ordinary Share capital. Pursuant to Rule 13 of the AIMRules this constitutes a related party transaction and the independent Directorsconsider having consulted with its Nominated Adviser that the terms of thetransaction are fair and reasonable insofar as its shareholders are concerned. R. James Macaleer received 20,114 Ordinary Shares, bringing his total holding ofthe Company to 19,871,563 representing 15.26 per cent of the Company's issuedOrdinary Share capital. Chief Executive Officer, Richard Morgan and President and Chief FinancialOfficer, Robert Bertoldi, who are also both Board members, have received NewOrdinary Shares as part of their incentive compensation. Richard Morgan received379,056 Ordinary Shares priced at 22p, bringing his total holdings of theCompany to 21,173,211 representing 16.26 per cent of the Company's issuedordinary share capital. Robert Bertoldi received 31,607 Ordinary Shares pricedat 22p, bringing his total holdings of the Company to 5,674,844 representing4.36 per cent of the Company's issued Ordinary Share capital. In addition to the 410,663 Ordinary Shares issued to Richard Morgan and RobertBertoldi, 50,893 Ordinary Shares were also issued to five employees of theCompany as part of their incentive compensation. Admission of the 1,658,261 New Ordinary Shares, ranking pari passu, is expectedon 11 April 2008. Following admission of the New Ordinary Shares, the Company will have130,196,893 ordinary shares in issue with each ordinary share holding one votingright. For further information please contact Amphion Innovations plcCharlie Morgan, Director of Communications+1 212 210 6224 Cardew GroupTim Robertson/ Jamie Milton/ Matthew Law+44 020 7930 0777 Charles Stanley Securities - Nominated AdviserMark Taylor / Freddy Crossley+44 20 7149 6000 About Amphion Innovations plc Amphion (LSE: AMP) builds shareholder value in high growth companies in themedical and technology sectors, by using a focused, hands-on company buildingapproach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 10 Partner Companies developing proventechnologies targeting substantial commercial marketplaces, each in excess of $1billion. Each Partner Company is chosen with the goal of achieving an exitvaluation in excess of $100 million. On the web: www.amphionplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Dec 20177:01 amRNSComment on Polarean Fund Raise
22nd Dec 20177:00 amRNSRestructure of Loan and Additional Drawdown
5th Dec 20177:00 amRNSIssue of Shares
23rd Nov 20177:00 amRNSFurther Update on Polarean Imaging Limited
10th Nov 20177:00 amRNSUpdate on Polarean Imaging Limited
2nd Nov 20177:00 amRNSOrder Dismissing DataTern Case
11th Oct 20177:00 amRNSRelated Party Transaction
5th Oct 20177:00 amRNSPartner Company releases positive clinical results
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
25th Sep 20177:00 amRNSSale of Partner Company Shares
30th Aug 20177:00 amRNSSale of partner company shares
30th Aug 20177:00 amRNSHolding(s) in Company
1st Aug 20175:19 pmRNSAGM Statement
28th Jun 20177:00 amRNSFinal Results
31st May 20177:00 amRNSPartner Company m2m Imaging merger update
22nd May 20174:36 pmRNSAdditional Draw Down on Loan Facility
7th Feb 20177:00 amRNSAdditional Draw Down on Loan Facility
1st Feb 20175:18 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
16th Dec 20163:07 pmRNSDirector/PDMR Shareholding
9th Dec 20163:50 pmRNSDirector/PDMR Shareholding
24th Nov 20162:15 pmRNSHolding(s) in Company
8th Sep 20167:00 amRNSRe-negotiated terms of Motif CPN
7th Sep 20167:00 amRNSInterim Results for the six months to 30 June 2016
22nd Aug 20163:58 pmRNSAdditional Draw Down on Loan Facility
3rd Aug 20164:13 pmRNSHolding(s) in Company
29th Jul 20167:00 amRNSResults of AGM and Directorate Change
18th Jul 20164:33 pmRNSTransfer of Shares
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:00 amRNSAdditional Draw Down on Loan Facility
23rd Jun 20167:00 amRNSFinal Results
29th Apr 20164:02 pmRNSAdditional Terms on Loan Facility
28th Apr 20167:00 amRNSAdditional Draw Down on Loan Facility
7th Apr 20167:00 amRNSAmphion settles contested arbitration ruling
3rd Mar 20167:00 amRNSConvertible Promissory Note Extended
7th Jan 20167:00 amRNSDirectors' Dealings
5th Jan 20167:00 amRNSConvertible Promissory Note Terms Extended
26th Nov 20157:00 amRNSAdditional Draw on Loan Facility
5th Nov 20157:00 amRNSPartner Company m2m Imaging Corp. to merge
30th Oct 20154:20 pmRNSDeath of a Director - Replacement
30th Oct 20153:50 pmRNSDeath of a Director
17th Sep 20157:00 amRNSAmphion to present in London
16th Sep 20157:00 amRNSDirectors' Dealings
10th Sep 20157:00 amRNSDataTern Receives Favourable Ruling
3rd Sep 20157:00 amRNSInterim Results
28th Aug 20159:08 amRNSHolding(s) in Company
7th Aug 20155:15 pmRNSResult of AGM
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.